AXL and metabolic dysfunction-associated steatotic liver disease: However, a few experimental reports mentioned in Table 1 demonstrate the use of RTK inhibitors such as Gefitinib, Bemcentinib and Sunitinib targeting EGFR, AXL and VEGFR respectively in NAFLD management.